{"id":"fibrinogen","rwe":[],"_fda":{"id":"a6dcd8af-ccd7-4b27-880a-c7da5c7e6efc","set_id":"0c324332-290f-413f-820c-8c9a971a2766","openfda":{"nui":["N0000184169","N0000175979","M0002684"],"unii":["6K15ABL77G","N94833051K"],"route":["TOPICAL"],"rxcui":["1001591","1001593","1014303","1014305"],"spl_id":["a6dcd8af-ccd7-4b27-880a-c7da5c7e6efc"],"brand_name":["TachoSil"],"spl_set_id":["0c324332-290f-413f-820c-8c9a971a2766"],"package_ndc":["83078-701-99","83078-701-00","83078-701-01","83078-704-99","83078-704-00","83078-704-01","83078-702-99","83078-702-00","83078-702-02"],"product_ndc":["83078-701","83078-704","83078-702"],"generic_name":["THROMBIN HUMAN AND FIBRINOGEN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Blood Coagulation Factors [CS]"],"pharm_class_pe":["Increased Coagulation Activity [PE]"],"substance_name":["FIBRINOGEN HUMAN","HUMAN THROMBIN"],"pharm_class_epc":["Human Blood Coagulation Factor [EPC]"],"manufacturer_name":["Corza Medical GmbH"],"application_number":["BLA125351"],"is_original_packager":[true]},"version":"7","pregnancy":["8.1 Pregnancy Risk Summary A review of available data suggests that major birth defects occur in 2-4% of the U.S. general population and that miscarriage occurs in 15-20% of clinically recognized pregnancies, regardless of drug exposure. Animal reproduction studies have not been conducted with TachoSil. There are no adequate and well-controlled studies in pregnant women. It is also not known whether TachoSil can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. TachoSil should be administered to pregnant women only if clearly needed."],"description":["11 DESCRIPTION TachoSil Fibrin Sealant Patch is a sterile, bioabsorbable combination product comprised of two active substances (human plasma-derived fibrinogen and human plasma-derived thrombin) coated onto a collagen sponge of equine origin. The collagen sponge serves as a flexible and mechanically stable carrier for the active substances to facilitate application of the human fibrinogen and thrombin to the wound surface. The active side of the patch is yellow in color due to the presence of a colorant riboflavin (E101); and the non-active side is off-white in color. Each square inch of the patch contains approximately 35.5 mg of human fibrinogen and 12.9 units of human thrombin. Other inactive ingredients include equine collagen, human albumin, sodium chloride, sodium citrate, and L‑arginine hydrochloride. TachoSil is sterilized by gamma irradiation after completion of inner and outer packaging, resulting in a sterile product in a sterile inner package. Viral Clearance The active biological substances of TachoSil (human fibrinogen and human thrombin) are manufactured from pooled human plasma collected in facilities in the United States. Human plasma is tested by a Nucleic Acid Test (NAT) for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus-1 (HIV-1). NAT testing for hepatitis A virus (HAV) and parvovirus B19 is also performed. Human plasma is also tested for the presence of hepatitis B surface antigen (HBsAg), and antibodies to hepatitis C virus (anti-HCV) and human immunodeficiency viruses types 1 and 2 (anti-HIV 1/2). The manufacturing procedure for each TachoSil component and final product include processing steps designed to reduce the risk of viral transmission. In particular, the virus clearance steps in the manufacture of human fibrinogen and thrombin include pasteurization, precipitation and adsorption. The virus clearance step in the manufacture of the collagen sponge is the pH treatment. The virus clearance capacity of these procedures in the manufacture of fibrinogen, thrombin and collagen sponge has been validated using viruses with a wide range of physicochemical characteristics. These in vitro validation studies were conducted using samples from manufacturing intermediates spiked with virus suspensions of known titers followed by further processing under conditions equivalent to those in the respective manufacturing steps. The cumulative virus reduction factors (expressed as log 10 ) are shown in Table 5 for each virus tested. Table 5. Cumulative Virus Reduction Factors for the Components of TachoSil Cumulative Reduction Factors for Virus Removal/Inactivation of Human Thrombin Virus Reduction Factors [log 10 ] Manufacturing step Enveloped Viruses Non-enveloped Viruses HIV HIV: Human Immunodeficiency Virus, HSV HSV: Herpes Simplex Virus BVDV BVDV: Bovine Viral Diarrhea Virus PRV PRV: Pseudorabies Virus CPV CPV: Canine parvovirus HAV HAV: Hepatitis A Virus Pasteurization, precipitation and adsorption steps 15.0 20.4 13.2 16.3 5.4 8.4 Cumulative Reduction Factors for Virus Removal/Inactivation of Human Fibrinogen Virus Reduction Factors [log 10 ] Manufacturing step Enveloped Viruses Non-enveloped Viruses HIV PRV BVDV WNV WNV: West Nile Virus, only single manufacturing step validated CPV HAV Pasteurization, precipitation and lyophilization steps 9.6 8.8 11.2 8.3 4.9 8.6 Reduction Factors for Virus Removal/Inactivation of the Collagen Sponge (equine) Virus Reduction Factors [log 10 ] Manufacturing step Enveloped Viruses Non-enveloped Viruses PRV PI-3 PI-3: Parainfluenza Virus type 3 PPV PPV: Porcine Parvovirus Reo3 Reo 3: ReoVirus type 3 pH treatment 5.7 5.9 --- --- A validation study was also conducted to evaluate the capacity for gamma irradiation to inactivate and/or remove viruses in the final TachoSil product. The virus reduction factors (expressed as log 10 ) are shown in Table 6 for each virus tested. Table 6. Virus Reduction Factors for TachoSil Final Sterilization by Gamma Irradiation Reduction Factor of Gamma Irradiation (Final Sterilization of TachoSil) Virus Reduction Factors [log 10 ] Enveloped Viruses Non-enveloped Viruses Manufacturing step PRV PRV: Pseudorabies Virus PI-3 PI-3: Parainfluenza Virus type 3 PPV PPV: Porcine Parvovirus Reo3 Reo 3: ReoVirus type 3 Gamma Irradiation 4.7 4.0 3.0 6.2 All infections considered by a physician possibly to have been transmitted by this product should be reported to Corza [see Warnings and Precautions (5.7) ] ."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Each TachoSil patch is packaged individually in a tray with lidding. This is placed in an outer pouch with a desiccant bag and packaged into a folding carton. TachoSil is supplied in the following pack sizes: Package with 1 patch of 3.7 inch x 1.9 inch (9.5 cm x 4.8 cm) (NDC 83078-701-01) Package with 2 patches of 1.9 inch x 1.9 inch (4.8 cm x 4.8 cm) (NDC 83078-702-02) Storage Use TachoSil before expiration date indicated on the package. Store unopened packages of TachoSil between 2ºC and 25ºC. TachoSil does not require refrigeration. Do not freeze. Do not use if package is opened or damaged."],"geriatric_use":["8.5 Geriatric Use Clinical trials to date included 326 patients older than 65 years of age receiving TachoSil. No overall differences in safety or effectiveness were observed between the elderly and younger patients, however, greater susceptibility of some older patients to adverse reactions cannot be ruled out."],"pediatric_use":["8.4 Pediatric Use The use of TachoSil has been studied in patients aged one month to 16 years; use in children under the age of one month may be unsafe or ineffective due to small size and limited ability to apply the patch as recommended. Use of TachoSil in the one month to 16 years age group is supported by evidence from adequate and well-controlled studies of TachoSil in adults with additional data from two clinical trials, which included 36 pediatric patients at the age of 16 years or younger. The data supports the use of TachoSil for hemostasis in pediatric patients undergoing cardiovascular and hepatic surgery [see Clinical Studies (14.3) ] ."],"effective_time":"20251008","clinical_studies":["14 CLINICAL STUDIES 14.1 Cardiovascular An open-label, multi-center, randomized, parallel-group study comparing TachoSil with comparator (hemostatic fleece without additional active coagulation stimulating compounds) treatment was conducted to evaluate TachoSil for control of bleeding in 119 patients undergoing cardiovascular surgery requiring cardiopulmonary bypass procedure. Of the 119 subjects, 88 (74%) were male and 31 (26%) female. Mean (range) age was 67 (23 to 86) years; subjects older than 65 years constituted 58% of the male and 74% of the female population. All subjects were White/Caucasian. In the Intent-to-Treat (ITT) population, 59 patients were randomized to treatment with TachoSil and 60 patients were randomized to treatment with the comparator. A larger proportion of patients in the TachoSil treatment group (44/59; 75%) than in the comparator treatment group (20/60; 33%) achieved hemostasis within three minutes, which was a statistically significant difference (p<0.0001). Fifty-six out of 59 (95%) patients in the TachoSil treatment group achieved hemostasis at six minutes compared to 43 out of 60 (72%) in the comparator treatment group, which also was statistically significant (p=0.0006) (see Table 7). Table 7. Efficacy Results in Cardiovascular Surgery, by Treatment, Intent-to-Treat Population Treatment Total number of patients who achieved hemostasis Percentage of patients who achieved hemostasis 95% CI for proportion Normal approximation to the binominal distribution is used to construct the asymptotic confidence intervals p-value Cochran-Mantel-Haenszel test controlling for center Hemostasis at 3 min TachoSil (n=59) 44 75% [0.635; 0.857] <0.0001 Comparator Hemostatic fleece material without additional active coagulation stimulating compounds (n=60) 20 33% [0.214; 0.453] Hemostasis at 6 min TachoSil (n=59) 56 95% [0.893;1.000] 0.0006 Comparator (n=60) 43 72% [0.603; 0.831] 14.2 Hepatic A randomized, open-label, parallel group, multi-center trial comparing TachoSil with comparator was conducted to evaluate TachoSil for the secondary treatment of local bleeding in patients undergoing hepatic surgery. A total of 114 patients were randomized to treatment with TachoSil and 110 patients were randomized to treatment with comparator. A similar proportion of male patients and female patients were randomly assigned in the trial (53% and 47%, respectively). The mean (SD) age of patients was 58.1 (13.95) years and in both treatment groups approximately 30% of the patients were above 65 years. The majority of patients were White/Caucasian (80%) and the most common ethnicity was non-Hispanic/non-Latino (88%). A larger proportion of patients in the TachoSil treatment group (81%) than in the comparator treatment group (50%) achieved hemostasis within the first three minutes after treatment application. The primary analysis of the proportion of patients who achieved hemostasis within three minutes showed a statistically significant difference between treatment groups in favor of TachoSil (p<0.001) and obtained a clinical relevant difference between the two groups defined from the estimated odds ratio (see Table 8). With respect to one of the two secondary endpoints, 108 (95%) patients in the TachoSil group and 84 (76%) patients in the comparator group achieved hemostasis within five minutes in which the secondary analysis also showed a statistically significant difference between the group in favor of TachoSil (p<0.001, multiplicity adjusted) (see Table 8). Table 8. Efficacy Results in Hepatic Surgery, by Treatment, Intent-To-Treat Population Treatment Total number of patients who achieved hemostasis Percentage of patients who achieved hemostasis Odds ratio [95% CI] p-value Hochberg's adjustment for multiplicity Hemostasis at 3 min TachoSil (n=114) 92 81% 4.87 [2.55; 9.29] <0.001 Comparator Hemostatic fleece material made of oxidized cellulose polymer (n=110) 55 50% Hemostasis at 5 min TachoSil (n=114) 108 95% 6.24 [2.39;16.30] <0.001 Comparator (n=110) 84 76% Time to hemostasis Analyzed by a log rank test for equality over treatments. Patients who did not achieve hemostasis after 10 minutes were censored in the analysis. - - - <0.001 TachoSil (n=114) Comparator (n=110) 14.3 Pediatric In a pediatric subset of a randomized, open-label, parallel group, multi-center trial comparing TachoSil with comparator the efficacy of TachoSil for the secondary treatment of local bleeding in pediatric patients undergoing hepatic surgery was evaluated. In the randomized part of the study, eight patients were treated with TachoSil and nine patients were treated with the comparator. After the randomization phase, an additional 12 patients were treated with TachoSil in a single extension arm to reach 20 patients exposed to TachoSil. A similar proportion of male and female pediatric patients were treated overall in the trial (48% and 52%, respectively). The majority of patients were White/Caucasian (79%) and the most common ethnicity was non-Hispanic/non-Latino (69%). The mean age was slightly higher in the TachoSil group (4.58 years; range 0.4, 13.0 years) than in the comparator group (3.77 years; range 0.4, 16.0 years). A larger proportion of the patients in the TachoSil group (7/8 [88%]) than in the comparator group (4/9 [44%]) achieved hemostasis within three minutes in the randomized part of the study. The results were similar considering the whole set of pediatric patients exposed to TachoSil (17/20 [85%]) (see Table 9) . No statistical testing was performed of the difference between the two groups due to the small sample size. Seven patients in the TachoSil group (88%) and seven patients in the comparator group (78%) achieved hemostasis within five minutes (see Table 9) . Table 9. Achievement of Hemostasis of Pediatric Patients Undergoing Hepatic Surgery, Intent-To-Treat Population/Safety Population Treatment Total number of achieved hemostasis Percentage of patients Exact [95% CI] Hemostasis at 3 min TachoSil (n=8) 7 88% [47.3, 99.7] Comparator Hemostatic fleece material made of oxidized cellulose polymer (n=9) 4 44% [13.7, 78.8] Hemostasis at 5 min TachoSil (n=8) 7 88% [47.3, 99.7] Comparator (n=9) 7 78% [40.0, 97.2] All TachoSil Patients Safety analysis set Hemostasis at 3 min 17 85% [62.1, 96.8] TachoSil (n=20) Hemostasis at 5 min 19 95% [75.1, 99.9] TachoSil (n=20) In another clinical study, 16 pediatric patients were included in a prospective, multi-center, uncontrolled, study where TachoSil was used in connection with resection of the liver with or without segmental liver transplantation. The analysis of the efficacy parameter, time to hemostasis, showed that 13 of 16 patients achieved hemostasis within three minutes after application of TachoSil. One patient obtained hemostasis eight minutes after treatment application and two subjects failed to achieve satisfactory hemostasis within 10 minutes, which necessitated alternative hemostatic measures. The estimated proportion of patients achieving hemostasis within three minutes was 81%, which is considered similar to results seen in the randomized controlled study."],"adverse_reactions":["6 ADVERSE REACTIONS The adverse reactions reported in more than one percent of patients during clinical trials were anemia, nausea and vomiting, fever, abdominal pain, increased white blood cell count, ascites, itching, atrial fibrillation, pleural effusion, gastrointestinal hemorrhage, wound infection, hypophosphatemia, urinary tract infection, and post-procedural bile leakage in hepatic surgery. The most common adverse reactions reported in >1% of patients during clinical trials were anemia, nausea and vomiting, fever, abdominal pain, increased white blood cell count, ascites, itching, atrial fibrillation, pleural effusion, gastrointestinal hemorrhage, wound infection, hypophosphatemia, urinary tract infection and post-procedural bile leakage in hepatic surgery. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Corza Medical GmbH at 1-800-997-1067 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Cardiovascular Surgery In the cardiovascular trial, the most frequently reported adverse reactions were atrial fibrillation and pleural effusion. Seventy-four percent (74%) of patients treated with TachoSil and 75% of comparator treated patients experienced one or more clinically relevant adverse reactions (see Table 2) . Table 2. Most Frequent Adverse Reactions (Cardiovascular Trial) Adverse Reaction TachoSil Comparator Comparator: Hemostatic fleece material without additional active coagulation stimulating compounds. N = 62 As treated population (safety data set). n (%) N = 57 n (%) Atrial fibrillation 18 (29%) 14 (25%) Pleural effusion 14 (23%) 11 (19%) Pyrexia 4 (6%) 3 (5%) Hepatic Surgery In the hepatic surgery trial, the most frequently reported adverse reactions were nausea and anemia (see Table 3). Ninety-four percent (94%) of patients treated with TachoSil and 94% of comparator treated patients experienced one or more clinically relevant adverse reactions. Table 3. Most Frequent Adverse Reactions (Hepatic Resection Trial) Adverse Reaction TachoSil Comparator Comparator: Hemostatic fleece material without additional active coagulation stimulating compounds. N = 114 As treated population (safety data set). n (%) N = 109 n (%) Nausea 34 (30%) 29 (27%) Anemia 26 (23%) 23 (21%) Post-operative bile leakage was observed in 8 (7%) of patients after treatment with TachoSil and 13 (12%) after treatment with comparator. Immunogenicity Antibodies against components of fibrin sealant/hemostatic products may occur. However in a clinical trial with human fibrinogen/human thrombin sponge (patch) in hepatic surgery, in which patients were investigated for the development of antibodies, 26% of the 96 patients tested and treated with human fibrinogen/human thrombin sponge (patch) developed antibodies to equine collagen. The equine collagen antibodies that developed in some patients after human fibrinogen/human thrombin sponge (patch) use were not reactive with human collagen. One patient developed antibodies to human fibrinogen. There were no adverse events attributable to the development of human fibrinogen or equine collagen antibodies. There is very limited clinical data available regarding re-exposure of the human fibrinogen/human thrombin sponge (patch). Two subjects have been re-exposed in a clinical trial and have not reported any immune-mediated adverse events, however, their antibody status to collagen or fibrinogen is unknown. Pediatric Clinical Trial Experience In pediatric patients, the most frequently reported adverse reactions were diarrhea, hypertension and increased transaminases (see Table 4). Ninety-four percent (94%) of patients treated with TachoSil and 100% of comparator treated patients experienced one or more clinically relevant adverse reactions. Table 4. Most Frequent Adverse Reactions in Pediatric Patients (All Trials) Adverse Reaction TachoSil Comparator Comparator: Hemostatic fleece material compounds without additional active coagulation stimulating compounds. N = 36 As treated population (safety data set). n (%) N = 9 n (%) Diarrhea 6 (17%) 0 Hypertension 6 (17%) 1 (11%) Transaminases Increased 4 (11%) 0 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of TachoSil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been reported in postmarketing experience with TachoSil: General disorders and administration site conditions : adhesions, drug ineffective or non-adherence of TachoSil, inflammation, granuloma, catheter-related complication, multi-organ failure Injury, poisoning and procedural complications : foreign body trauma, post-procedural pulmonary embolism Vascular disorders : thrombosis Infections and infestations : hepatitis C Respiratory, thoracic and mediastinal disorders : respiratory distress, laryngeal edema, hemothorax Blood and lymphatic system disorders : splenic hemorrhage, eosinophilia Renal and urinary disorders : renal artery thrombosis, renal failure Endocrine disorders : parathyroid disorder Eye disorders : mydriasis Nervous system disorders : nerve compression Gastrointestinal disorders: intestinal obstruction (in abdominal surgeries), ileus (in abdominal surgeries)"],"contraindications":["4 CONTRAINDICATIONS Do not use TachoSil for: • Intravascular application. Bleeding from large defects in visible arteries or veins where the injured vascular wall requires repair and maintenance of vessel patency or where there would be persistent exposure of TachoSil to blood flow during absorption of the product. This can result in life-threatening thromboembolic events [see Warnings and Precautions (5.1) ] . • Individuals known to have anaphylactic or severe systemic reaction to human blood products or horse proteins [see Warnings and Precautions (5.2) ] . Do not apply TachoSil intravascularly. Intravascular application of TachoSil may result in life-threatening thromboembolic events. ( 4 ) Do not use TachoSil in individuals with known hypersensitivity to human blood products or horse proteins. ( 4 )"],"description_table":["
Table 5. Cumulative Virus Reduction Factors for the Components of TachoSil
Cumulative Reduction Factors for Virus Removal/Inactivation of Human Thrombin
Virus Reduction Factors [log10]
Manufacturing stepEnveloped VirusesNon-enveloped Viruses
HIVHIV: Human Immunodeficiency Virus,HSVHSV: Herpes Simplex VirusBVDVBVDV: Bovine Viral Diarrhea VirusPRVPRV: Pseudorabies VirusCPVCPV: Canine parvovirusHAVHAV: Hepatitis A Virus
Pasteurization, precipitation and adsorption steps15.020.413.216.35.48.4
Cumulative Reduction Factors for Virus Removal/Inactivation of Human Fibrinogen
Virus Reduction Factors [log10]
Manufacturing stepEnveloped VirusesNon-enveloped Viruses
HIVPRVBVDVWNV WNV: West Nile Virus, only single manufacturing step validatedCPVHAV
Pasteurization, precipitation and lyophilization steps9.68.811.28.34.98.6
Reduction Factors for Virus Removal/Inactivation of the Collagen Sponge (equine)
Virus Reduction Factors [log10]
Manufacturing stepEnveloped VirusesNon-enveloped Viruses
PRVPI-3PI-3: Parainfluenza Virus type 3PPVPPV: Porcine ParvovirusReo3Reo 3: ReoVirus type 3
pH treatment5.75.9------
","
Table 6. Virus Reduction Factors for TachoSil Final Sterilization by Gamma Irradiation
Reduction Factor of Gamma Irradiation (Final Sterilization of TachoSil)
Virus Reduction Factors [log10]
Enveloped VirusesNon-enveloped Viruses
Manufacturing stepPRVPRV: Pseudorabies VirusPI-3PI-3: Parainfluenza Virus type 3PPVPPV: Porcine ParvovirusReo3Reo 3: ReoVirus type 3
Gamma Irradiation4.74.03.06.2
"],"how_supplied_table":["
Package with 1 patch of 3.7 inch x 1.9 inch (9.5 cm x 4.8 cm)(NDC 83078-701-01)
Package with 2 patches of 1.9 inch x 1.9 inch (4.8 cm x 4.8 cm)(NDC 83078-702-02)
"],"mechanism_of_action":["12.1 Mechanism of Action The mechanism of action of TachoSil is based on the interaction between the active biological substances (human fibrinogen and human thrombin) and the physiology of the fibrin clot formation (Fig. 3A) . Upon contact with a bleeding wound surface, the active substances coated onto the equine collagen patch become dissolved and partly diffuse into the wound surface. The subsequent fibrinogen-thrombin reaction initiates the last step in the cascade of biochemical reactions-conversion of fibrinogen into fibrin monomers that further polymerize to form the fibrin clot. Hemostasis is achieved when the formed fibrin clot adheres the collagen patch to the wound surface, thus providing a physical barrier to bleeding (Fig 3B) . TachoSil exhibits flexibility to accommodate for the physiological movements of tissues and organs and can withstand pressures up to 61.4 hPa (46.1 mmHg). Figure 3: Scanning Electron Microscopy Photos of TachoSil A . The side view of the TachoSil patch shows the coating of the human plasma components anchored to the indentations of the collagen carrier. B . The deposition of a fibrin clot formed from fibrinogen and thrombin of the coating results in hemostasis and conglutination of the TachoSil patch to the wound surface. 12a 12b"],"teratogenic_effects":["Risk Summary A review of available data suggests that major birth defects occur in 2-4% of the U.S. general population and that miscarriage occurs in 15-20% of clinically recognized pregnancies, regardless of drug exposure. Animal reproduction studies have not been conducted with TachoSil. There are no adequate and well-controlled studies in pregnant women. It is also not known whether TachoSil can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. TachoSil should be administered to pregnant women only if clearly needed."],"recent_major_changes":["Dosage and Administration ( 2.2 ) 08/2025 Warning and Precautions ( 5.6 ) 08/2025"],"storage_and_handling":["Storage Use TachoSil before expiration date indicated on the package. Store unopened packages of TachoSil between 2ºC and 25ºC. TachoSil does not require refrigeration. Do not freeze. Do not use if package is opened or damaged."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of TachoSil is based on the interaction between the active biological substances (human fibrinogen and human thrombin) and the physiology of the fibrin clot formation (Fig. 3A) . Upon contact with a bleeding wound surface, the active substances coated onto the equine collagen patch become dissolved and partly diffuse into the wound surface. The subsequent fibrinogen-thrombin reaction initiates the last step in the cascade of biochemical reactions-conversion of fibrinogen into fibrin monomers that further polymerize to form the fibrin clot. Hemostasis is achieved when the formed fibrin clot adheres the collagen patch to the wound surface, thus providing a physical barrier to bleeding (Fig 3B) . TachoSil exhibits flexibility to accommodate for the physiological movements of tissues and organs and can withstand pressures up to 61.4 hPa (46.1 mmHg). Figure 3: Scanning Electron Microscopy Photos of TachoSil A . The side view of the TachoSil patch shows the coating of the human plasma components anchored to the indentations of the collagen carrier. B . The deposition of a fibrin clot formed from fibrinogen and thrombin of the coating results in hemostasis and conglutination of the TachoSil patch to the wound surface. 12a 12b"],"indications_and_usage":["1 INDICATIONS AND USAGE TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. Limitations for Use TachoSil cannot safely or effectively be used in place of sutures or other form of mechanical ligation for the treatment of major arterial or venous bleeding. Not for use in children under one month of age. TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. ( 1 ) Limitations for Use Not for use in place of sutures or other forms of mechanical ligation in treatment of major arterial or venous bleeding. ( 1 ) Not for use in children under one month of age. ( 8.4 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Thrombosis can occur if TachoSil is applied intravascularly. Ensure that TachoSil is applied to the surface of cardiac, vascular or hepatic tissue only. ( 5.1 ) • Can cause hypersensitivity or allergic/anaphylactoid reactions with first time or repetitive application. ( 5.2 ) • Avoid use in contaminated areas of the body or in the presence of an active infection. ( 5.3 ) • TachoSil contains collagen, which may adhere to bleeding surfaces. May carry a risk of gastrointestinal obstruction in abdominal surgery due to tissue adhesions. To prevent the development of tissue adhesions at undesired sites, ensure tissue areas outside the application area are adequately cleansed before administration of TachoSil. ( 5.4 ) • Avoid packing in cavities or closed spaces, because this may cause compression of underlying tissue. ( 5.5 ) • Use the least number of patches required to cover the entire bleeding area. Do not pack. Remove any unattached pieces of TachoSil. ( 5.6 ) • May carry a risk of transmitting infectious agents, such as viruses, and theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent, and the Creutzfeldt-Jakob disease (CJD) agents, despite manufacturing steps designed to reduce the risk of viral transmission. ( 5.7 ) 5.1 Thrombosis Thrombosis can occur if TachoSil is applied intravascularly. Ensure that TachoSil is applied to the surface of cardiac, vascular, or hepatic tissue only. 5.2 Hypersensitivity Reactions Hypersensitivity or allergic/anaphylactoid reactions may occur with TachoSil. Symptoms associated with allergic anaphylactic reactions include: flush, urticaria, pruritus, nausea, drop in blood pressure, tachycardia or bradycardia, dyspnea, severe hypotension and anaphylactic shock. These reactions may occur in patients receiving TachoSil for the first time or may increase with repetitive applications of TachoSil. 5.3 Infection Avoid application to contaminated or infected areas of the body, or in the presence of active infection. 5.4 Adhesions TachoSil contains collagen, which may adhere to bleeding surfaces. To prevent the development of tissue adhesions at undesired sites, ensure tissue areas outside the desired application area are adequately cleansed before administration of TachoSil [see Dosage and Administration (2.2 )] . Events of adhesions to gastrointestinal tissues leading to gastrointestinal obstruction have been reported with use in abdominal surgery carried out in proximity to the bowel. 5.5 Compression When placing TachoSil into cavities or closed spaces, avoid packing because this may cause compression of underlying tissue. 5.6 Non-Adherence or Dislodged Material Non-adherence has occurred after TachoSil application [see Postmarketing Experience (6.2) ]. Follow proper handling, preparation, and application procedures to reduce the risk of non-adherence of TachoSil [see Dosage and Administration (2.2) ]. Theoretically, excess patch material can become dislodged and migrate to other areas of the body. Use only minimum amount of TachoSil patches necessary to achieve hemostasis. Remove unattached pieces of TachoSil; if medically necessary [see Dosage and Administration (2.2) ] . 5.7 Transmissible Infectious Agents Because the biological components of this product are made from human blood, it may carry a risk of transmitting infectious agents (e.g., viruses), and theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent and the Creutzfeldt-Jakob disease (CJD) agent. The risk that TachoSil will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain virus infections, and by inactivating and removing, certain viruses [see Description (11) ] . Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Corza Medical GmbH, at telephone number 1-800-997-1067. The physician should discuss the risks and benefits of this product with the patient. Some viruses, such as parvovirus B19, are particularly difficult to remove or inactivate at this time. Parvovirus B19 most seriously affects pregnant women (fetal infection); immune-compromised individuals or individuals with an increased erythropoiesis (e.g., hemolytic anemia) [see Use in Specific Populations (8.1) and Patient Counseling Information (17) ] ."],"clinical_studies_table":["
Table 7. Efficacy Results in Cardiovascular Surgery, by Treatment, Intent-to-Treat Population
TreatmentTotal number of patients who achieved hemostasisPercentage of patients who achieved hemostasis95% CI for proportionNormal approximation to the binominal distribution is used to construct the asymptotic confidence intervalsp-valueCochran-Mantel-Haenszel test controlling for center
Hemostasis at 3 min
TachoSil (n=59)4475%[0.635; 0.857]<0.0001
ComparatorHemostatic fleece material without additional active coagulation stimulating compounds (n=60)2033%[0.214; 0.453]
Hemostasis at 6 min
TachoSil (n=59)5695%[0.893;1.000]0.0006
Comparator (n=60)4372%[0.603; 0.831]
","
Table 8. Efficacy Results in Hepatic Surgery, by Treatment, Intent-To-Treat Population
TreatmentTotal number of patients who achieved hemostasisPercentage of patients who achieved hemostasisOdds ratio [95% CI]p-valueHochberg's adjustment for multiplicity
Hemostasis at 3 min
TachoSil (n=114)9281%4.87 [2.55; 9.29]<0.001
ComparatorHemostatic fleece material made of oxidized cellulose polymer (n=110)5550%
Hemostasis at 5 min
TachoSil (n=114)10895%6.24 [2.39;16.30]<0.001
Comparator (n=110)8476%
Time to hemostasisAnalyzed by a log rank test for equality over treatments. Patients who did not achieve hemostasis after 10 minutes were censored in the analysis.---<0.001
TachoSil (n=114)
Comparator (n=110)
","
Table 9. Achievement of Hemostasis of Pediatric Patients Undergoing Hepatic Surgery, Intent-To-Treat Population/Safety Population
TreatmentTotal number of achieved hemostasisPercentage of patientsExact [95% CI]
Hemostasis at 3 min
TachoSil (n=8)788%[47.3, 99.7]
ComparatorHemostatic fleece material made of oxidized cellulose polymer (n=9)444%[13.7, 78.8]
Hemostasis at 5 min
TachoSil (n=8)788%[47.3, 99.7]
Comparator (n=9)778%[40.0, 97.2]
All TachoSil PatientsSafety analysis set
Hemostasis at 3 min1785%[62.1, 96.8]
TachoSil (n=20)
Hemostasis at 5 min1995%[75.1, 99.9]
TachoSil (n=20)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies to evaluate the carcinogenic potential of TachoSil or studies to determine the genotoxicity or the effect of TachoSil on fertility have not been performed. An assessment of the carcinogenic potential of TachoSil was completed to demonstrate minimal carcinogenic risk from product use. 13.2 Animal Toxicology and/or Pharmacology In a study conducted in swine, TachoSil was applied to liver wounds and showed progressive degradation. However, remnants of the TachoSil patch may remain present for more than 12 months. Histologic examination at 26 and 52 weeks revealed that granulation tissue encapsulates TachoSil remnants and forms a firm capsule around them. Remnants were found in all treated animals after 26 weeks (12/12) and in most animals (6/8) after 52 weeks. No other local reactivity or toxicities were noted."],"adverse_reactions_table":["
Table 2. Most Frequent Adverse Reactions (Cardiovascular Trial)
Adverse ReactionTachoSilComparatorComparator: Hemostatic fleece material without additional active coagulation stimulating compounds.
N = 62As treated population (safety data set). n (%)N = 57 n (%)
Atrial fibrillation18 (29%)14 (25%)
Pleural effusion14 (23%)11 (19%)
Pyrexia4 (6%)3 (5%)
","
Table 3. Most Frequent Adverse Reactions (Hepatic Resection Trial)
Adverse ReactionTachoSilComparatorComparator: Hemostatic fleece material without additional active coagulation stimulating compounds.
N = 114As treated population (safety data set). n (%)N = 109 n (%)
Nausea34 (30%)29 (27%)
Anemia26 (23%)23 (21%)
","
Table 4. Most Frequent Adverse Reactions in Pediatric Patients (All Trials)
Adverse ReactionTachoSilComparatorComparator: Hemostatic fleece material compounds without additional active coagulation stimulating compounds.
N = 36As treated population (safety data set). n (%)N = 9 n (%)
Diarrhea6 (17%)0
Hypertension6 (17%)1 (11%)
Transaminases Increased4 (11%)0
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Because TachoSil may cause the formation of clots in blood vessels if exposed intravascularly, advise patients to consult their physician if they experience chest pain, shortness of breath or difficulty speaking or swallowing, or leg tenderness or swelling [see Warnings and Precautions (5.1) ] . Instruct patients to consult their physician if symptoms of B19 virus infection appear (fever, drowsiness and chills) followed about two weeks later by a rash and joint pain. Parvovirus B19 most seriously affects pregnant women (fetal infection); immune-compromised individuals or individuals with an increased erythropoiesis (e.g., hemolytic anemia) [see Warnings and Precautions (5.7) ] . Advise patients that, because TachoSil is made from human blood, it may carry a risk of transmitting infectious agents (e.g., viruses), and theoretically, the Creutzfeldt-Jakob (CJD) agent [see Warnings and Precautions (5.7) ] ."],"spl_unclassified_section":["Manufactured by: Corza Medical Distribution GmbH, Austria Branch St. Peter Strasse 25 A-4020 Linz Austria Distributed by: Corza Medical GmbH Speditionstrasse 21 40221 Duesseldorf, Germany U.S. License No. 2294 TachoSil is a registered trademark licensed to Corza Medical GmbH All other trademarks are the property of their respective owners."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For topical use on cardiovascular or hepatic tissue only Determine the number of patches to be applied by the size of the bleeding area. Apply the yellow, active side of the patch to the bleeding area. When applying TachoSil, do not exceed the maximum number of patches shown in Table 1 [see Warnings and Precautions (5.6) ] . Table 1. Amount of Fibrinogen and Thrombin per Total Patch Size and Maximum Number of TachoSil Patches to be Applied TachoSil Patch Size Human Fibrinogen (mg) Human Thrombin (Units) Maximum Number of Patches to be Applied 3.7 inch x 1.9 inch (9.5 cm x 4.8 cm) 337.4 123.1 10 1.9 inch x 1.9 inch (4.8 cm x 4.8 cm) 170.5 62.2 14 Apply on the surface of cardiovascular or hepatic tissue only. • Determine the number of TachoSil patches to be applied by the size of the bleeding area. ( 2 ) • Apply the yellow, active side of the patch to the bleeding surface. ( 2 ) 2.1 Preparation for Application TachoSil comes ready to use in sterile packages and must be handled using sterile technique in aseptic conditions. Discard damaged packages as resterilization is not possible. When in the operating room, the outer aluminum foil pouch may be opened in a non-sterile environment (Fig. 1A) . The inner sterile blister must be opened in a sterile environment (Fig. 1B) . Remove the TachoSil patch from the blister (Fig. 1C) , which can be used as a container for pre-moistening of the patch, if needed. Determine the size of patch(es) to be applied to the bleeding surface. Select the appropriate TachoSil patch so that it extends 1 to 2 cm beyond the margins of the wound. The patch can be cut to the correct size and shape if desired (Fig. 1D) . If more than one patch is used, overlap patches by at least 1 cm. Prior to application, cleanse the area to be treated to remove disinfectants and other fluids. The fibrinogen and thrombin proteins can be denatured by alcohol, iodine or heavy metal ions. If any of these substances have been used to clean the wound area, thoroughly irrigate the area before the application of TachoSil. Apply TachoSil directly to the bleeding area either wet or dry. If applied wet, pre-moisten TachoSil in 0.9% saline solution and then apply immediately. In the case of a wet tissue surface (e.g., oozing bleeding) TachoSil may be applied without pre-moistening. Figure 1: Pictures illustrating steps for preparation for application of TachoSil A B C D 21a 21b 21c 21d 2.2 Method of Application To ensure TachoSil adheres effectively, follow the recommended handling, preparation, and application procedures. Incorrect handling may result in non-adherence and reduced efficacy of TachoSil. Cleanse surgical instruments, gloves and adjacent tissues with saline solution to reduce the adherence to the TachoSil patch. The white, inactive side of TachoSil may also adhere to surgical instruments (e.g., forceps), gloves or adjacent tissues covered with blood due to the affinity of collagen to blood. It is important to note that failure to adequately clean adjacent tissues may cause adhesions [see Warnings and Precautions (5.4) ] . Apply the yellow, active side of the patch to the bleeding area (Fig. 2A) and hold in place with gentle pressure applied through moistened gloves or a moist pad for at least three minutes (Fig. 2B) . To avoid pulling the patch loose, first place a clean surgical instrument at one end of the patch before relieving the pressure (Fig. 2C) . Gentle irrigation may also aid in removing the pre-moistened pad or gloved hand without removing TachoSil from the bleeding area. Leave TachoSil in place once it adheres to organ tissue. Only remove unattached TachoSil patches (or part of) and replace with new patches. TachoSil cannot be resterilized once removed from inner pouch. Discard unused, opened packages of TachoSil at the end of the procedure. Figure 2: Pictures illustrating steps for method of application of TachoSil A B C Record patient name and TachoSil batch number every time that TachoSil is administered to a patient. 22a 22b 22c 2.3 Retreatment If not satisfied with the placement of the patch, or if bleeding still occurs during or after the specified duration of compression, repeat application procedure above. Do not remove already applied TachoSil."],"mechanism_of_action_table":["
A. The side view of the TachoSil patch shows the coating of the human plasma components anchored to the indentations of the collagen carrier. B. The deposition of a fibrin clot formed from fibrinogen and thrombin of the coating results in hemostasis and conglutination of the TachoSil patch to the wound surface.
"],"spl_product_data_elements":["TachoSil THROMBIN HUMAN and FIBRINOGEN HUMAN THROMBIN HUMAN THROMBIN FIBRINOGEN HUMAN FIBRINOGEN HUMAN EQUINE COLLAGEN ALBUMIN HUMAN RIBOFLAVIN SODIUM CHLORIDE SODIUM CITRATE, UNSPECIFIED FORM ARGININE HYDROCHLORIDE active side TachoSil THROMBIN HUMAN and FIBRINOGEN HUMAN THROMBIN HUMAN THROMBIN FIBRINOGEN HUMAN FIBRINOGEN HUMAN EQUINE COLLAGEN ALBUMIN HUMAN RIBOFLAVIN SODIUM CHLORIDE SODIUM CITRATE, UNSPECIFIED FORM ARGININE HYDROCHLORIDE active side TachoSil THROMBIN HUMAN and FIBRINOGEN HUMAN THROMBIN HUMAN THROMBIN FIBRINOGEN HUMAN FIBRINOGEN HUMAN EQUINE COLLAGEN ALBUMIN HUMAN RIBOFLAVIN SODIUM CHLORIDE SODIUM CITRATE, UNSPECIFIED FORM ARGININE HYDROCHLORIDE active side"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge. The active side of the patch is yellow in color due to the presence of a colorant riboflavin (E101); and the non-active side is off-white in color. Strength: Each absorbable TachoSil patch contains: Per square inch: Human fibrinogen 23.2 – 47.7 mg (35.5 mg) Human thrombin 8.4 – 17.4 Units (12.9 U) Per square centimeter: Human fibrinogen 3.6 – 7.4 mg (5.5 mg) Human thrombin 1.3 – 2.7 Units (2.0 U) TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge. Each absorbable patch contains, per square inch (inch 2 ): human fibrinogen 23.2 to 47.7 mg (35.5 mg); human thrombin 8.4 to 17.4 Units (12.9 U) per cm 2 : human fibrinogen 3.6 to 7.4 mg (5.5 mg); human thrombin 1.3 to 2.7 Units (2.0 U). ( 3 )"],"clinical_pharmacology_table":["
A. The side view of the TachoSil patch shows the coating of the human plasma components anchored to the indentations of the collagen carrier. B. The deposition of a fibrin clot formed from fibrinogen and thrombin of the coating results in hemostasis and conglutination of the TachoSil patch to the wound surface.
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary A review of available data suggests that major birth defects occur in 2-4% of the U.S. general population and that miscarriage occurs in 15-20% of clinically recognized pregnancies, regardless of drug exposure. Animal reproduction studies have not been conducted with TachoSil. There are no adequate and well-controlled studies in pregnant women. It is also not known whether TachoSil can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. TachoSil should be administered to pregnant women only if clearly needed. 8.2 Lactation It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TachoSil is administered to nursing mothers. 8.4 Pediatric Use The use of TachoSil has been studied in patients aged one month to 16 years; use in children under the age of one month may be unsafe or ineffective due to small size and limited ability to apply the patch as recommended. Use of TachoSil in the one month to 16 years age group is supported by evidence from adequate and well-controlled studies of TachoSil in adults with additional data from two clinical trials, which included 36 pediatric patients at the age of 16 years or younger. The data supports the use of TachoSil for hemostasis in pediatric patients undergoing cardiovascular and hepatic surgery [see Clinical Studies (14.3) ] . 8.5 Geriatric Use Clinical trials to date included 326 patients older than 65 years of age receiving TachoSil. No overall differences in safety or effectiveness were observed between the elderly and younger patients, however, greater susceptibility of some older patients to adverse reactions cannot be ruled out."],"dosage_and_administration_table":["
Table 1. Amount of Fibrinogen and Thrombin per Total Patch Size and Maximum Number of TachoSil Patches to be Applied
TachoSil Patch SizeHuman Fibrinogen (mg)Human Thrombin (Units)Maximum Number of Patches to be Applied
3.7 inch x 1.9 inch (9.5 cm x 4.8 cm)337.4123.110
1.9 inch x 1.9 inch (4.8 cm x 4.8 cm)170.562.214
","
A BCD
","
ABC
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 1 Patch Blister Pack Pouch Carton - NDC 83078-701-01 NDC 83078-701-01 Fibrin Sealant Patch TachoSil ® 3.7 inch x 1.9 inch (9.5 cm x 4.8 cm) Contents: 1 absorbable fibrin sealant patch Single use only Topical use only Do not use intravascularly Store at 2°C to 25°C (36°F to 77°F) Do not freeze Directions for use: See package insert Do not use if package is opened or damaged Use immediately once the foil pouch is opened Do not resterilize Dispose of any unused product or waste material in accordance with local requirements Rx Only Product Code 1144922 Corza large","PRINCIPAL DISPLAY PANEL - 1 Patch Blister Pack Sample Pouch Carton - NDC 83078-704-01 NDC 83078-704-01 Fibrin Sealant Patch TachoSil ® Sample - Not for Sale 3.7 inch x 1.9 inch (9.5 cm x 4.8 cm) Contents: 1 absorbable fibrin sealant patch Single use only Topical use only Do not use intravascularly Store at 2°C to 25°C (36°F to 77°F) Do not freeze Directions for use: See package insert Do not use if package is opened or damaged Use immediately once the foil pouch is opened Do not resterilize Dispose of any unused product or waste material in accordance with local requirements Rx Only Product Code 6019646 Corza sample","PRINCIPAL DISPLAY PANEL - 2 Patch Blister Pack Pouch Carton NDC 83078-702-02 NDC 83078-702-02 Fibrin Sealant Patch TachoSil ® 1.9 inch x 1.9 inch (4.8 cm x 4.8 cm) Contents: 2 absorbable fibrin sealant patches Single use only Topical use only Do not use intravascularly Store at 2°C to 25°C (36°F to 77°F) Do not freeze Directions for use: See package insert Do not use if package is opened or damaged Use immediately once the foil pouch is opened Do not resterilize Dispose of any unused product or waste material in accordance with local requirements Rx Only Product Code 1144923 Corza midi"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies to evaluate the carcinogenic potential of TachoSil or studies to determine the genotoxicity or the effect of TachoSil on fertility have not been performed. An assessment of the carcinogenic potential of TachoSil was completed to demonstrate minimal carcinogenic risk from product use."]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"43 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"CEREBROSPINAL FLUID LEAKAGE","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"INTESTINAL OBSTRUCTION","source":"FDA FAERS","actionTaken":"11 reports"},{"date":"","signal":"PRODUCT ADHESION ISSUE","source":"FDA FAERS","actionTaken":"11 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"11 reports"},{"date":"","signal":"ABDOMINAL ABSCESS","source":"FDA FAERS","actionTaken":"10 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"8 reports"},{"date":"","signal":"HAEMATOMA","source":"FDA FAERS","actionTaken":"8 reports"},{"date":"","signal":"POST PROCEDURAL HAEMORRHAGE","source":"FDA FAERS","actionTaken":"8 reports"}],"commonSideEffects":[{"effect":"Skin graft failure","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Hematoma/seroma","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Hematoma","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"1%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Air embolism","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL2109072","moleculeType":"Unknown"},"aliases":["Riastap®, CSL Behring","Active drug","Riastap","Haemocomplettan","Fibrinogen Concentrate (Human) Injection [Fibryga]"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Fibrinogen","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:16:25.484130+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Fibrinogen","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:16:32.565467+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:16:31.162491+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fibrinogen","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:16:31.512774+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:16:24.238731+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:16:24.238762+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:16:24.238770+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:16:32.966866+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Fibrinogen exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:16:32.565386+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109072/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:16:32.220947+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA125351","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:16:24.238776+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"1b470116-54bc-4ef8-ae46-2fba06c3368b","title":"FESILTY (FIBRINOGEN, HUMAN-CHMT) KIT [GRIFOLS USA LLC]"},"ecosystem":[],"mechanism":{"drugClass":"Human Blood Coagulation Factor [EPC]"},"_scrapedAt":"2026-03-27T23:30:26.429Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Fibrinogen","title":"Fibrinogen","extract":"Fibrinogen is a glycoprotein complex, produced in the liver, that circulates in the blood of all vertebrates. During tissue and vascular injury, it is converted enzymatically by thrombin to fibrin and then to a fibrin-based blood clot. Fibrin clots function primarily to occlude blood vessels to stop bleeding. Fibrin also binds and reduces the activity of thrombin. This activity, sometimes referred to as antithrombin I, limits clotting. Fibrin also mediates blood platelet and endothelial cell spreading, tissue fibroblast proliferation, capillary tube formation, and angiogenesis and thereby promotes revascularization and wound healing."},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:16:35.606596+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05124041","phase":"NA","title":"Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-11-15","conditions":"Acute on Chronic Liver Failure, Variceal Hemorrhage, Cirrhosis, Liver","enrollment":262},{"nctId":"NCT07105904","phase":"","title":"Biological and Clinical Relevance of Quantra Viscoelastic Hemostatic Assay in Hemorrhagic Cardiac Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pitié-Salpêtrière Hospital","startDate":"2025-07-10","conditions":"Hemorrhage, Cardiac Surgery, Hemorrhagic Shock","enrollment":600},{"nctId":"NCT07182227","phase":"PHASE1, PHASE2","title":"PS-002 for the Treatment of IgA Nephropathy in Adults","status":"RECRUITING","sponsor":"Purespring Therapeutics Limited","startDate":"2026-02","conditions":"Immunoglobulin A (IgA) Nephropathy","enrollment":32},{"nctId":"NCT05889494","phase":"NA","title":"Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2025-03-24","conditions":"Postoperative Hemorrhage, Postoperative Anemia, Postoperative Blood Loss","enrollment":64},{"nctId":"NCT06617897","phase":"PHASE3","title":"Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2024-10-01","conditions":"Acquired Fibrinogen Deficiency","enrollment":90},{"nctId":"NCT00647478","phase":"","title":"System-IGF-1 Pathway and Alzheimer's Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-10","conditions":"Alzheimer's Disease, Mild Cognitive Impairment, Cognitive Function 1, Social","enrollment":693},{"nctId":"NCT07457879","phase":"","title":"Impact of the Reimbursement of Fibrinogen in Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Erasme University Hospital","startDate":"2026-03-20","conditions":"Cardiac Surgery","enrollment":450},{"nctId":"NCT04376762","phase":"PHASE4","title":"Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2021-10-26","conditions":"Pediatric HD, Bleeding","enrollment":31},{"nctId":"NCT07455591","phase":"PHASE4","title":"A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2024-01-01","conditions":"Osteo Arthritis of the Knee","enrollment":78},{"nctId":"NCT03560570","phase":"","title":"Study of Hemostasis in Patients With Congenital Disorder of Glycosylation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-01-01","conditions":"Congenital Disorders of Glycosylation","enrollment":57},{"nctId":"NCT05385952","phase":"NA","title":"GATT-Patch Versus TachoSil in Liver Surgery","status":"COMPLETED","sponsor":"GATT Technologies BV","startDate":"2022-08-04","conditions":"Intraoperative Bleeding, Hemorrhage, Surgical, Liver Diseases","enrollment":132},{"nctId":"NCT07442552","phase":"","title":"Perioperative Sepsis. An Epigenetic Perspective","status":"RECRUITING","sponsor":"Carol Davila University of Medicine and Pharmacy","startDate":"2026-01-20","conditions":"Sepsis Abdominal","enrollment":40},{"nctId":"NCT07437755","phase":"NA","title":"Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures","status":"RECRUITING","sponsor":"Grigore T. Popa University of Medicine and Pharmacy","startDate":"2025-06-01","conditions":"Liver Cirrhosis With Acute Decompensation","enrollment":116},{"nctId":"NCT07425600","phase":"","title":"Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-03-01","conditions":"Fibrinogen Deficiency in Complex Cardiac Surgery","enrollment":150},{"nctId":"NCT07422974","phase":"","title":"Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer","status":"RECRUITING","sponsor":"Osijek University Hospital","startDate":"2026-01-09","conditions":"Colorectal Carcinoma (CRC), Complications, Neoadjuvant Therapy","enrollment":68},{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT07407101","phase":"NA","title":"Impact of Filtration on Autologous Serum Eye Drops","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2026-04-30","conditions":"Dry Eye Syndrome (DES)","enrollment":10},{"nctId":"NCT07397689","phase":"","title":"Early Sepsis Recognition Tool","status":"NOT_YET_RECRUITING","sponsor":"KK Women's and Children's Hospital","startDate":"2026-02","conditions":"Infection, Sepsis","enrollment":40000},{"nctId":"NCT07400848","phase":"","title":"Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome","status":"RECRUITING","sponsor":"University of Bern","startDate":"2026-02-15","conditions":"Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue","enrollment":200},{"nctId":"NCT07097337","phase":"","title":"Point of Care Fibrinogen Measurement in Trauma Patients in the Emergency Department","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-11-01","conditions":"Trauma Induced Coagulopathy, Trauma Coagulopathy, Fibrinogen Deficiency","enrollment":150},{"nctId":"NCT05449834","phase":"PHASE3","title":"Fibrinogen Early In Severe Trauma StudY II","status":"RECRUITING","sponsor":"Australian and New Zealand Intensive Care Research Centre","startDate":"2022-11-21","conditions":"Trauma, Haemorrhagic Shock, Coagulopathy","enrollment":900},{"nctId":"NCT03846193","phase":"PHASE1, PHASE2","title":"FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD","status":"TERMINATED","sponsor":"Gyroscope Therapeutics Limited","startDate":"2018-12-17","conditions":"Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease","enrollment":56},{"nctId":"NCT04566445","phase":"PHASE2","title":"HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005","status":"TERMINATED","sponsor":"Gyroscope Therapeutics Limited","startDate":"2020-09-28","conditions":"Dry Age-related Macular Degeneration","enrollment":255},{"nctId":"NCT04437368","phase":"PHASE2","title":"EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005","status":"TERMINATED","sponsor":"Gyroscope Therapeutics Limited","startDate":"2019-04-26","conditions":"Dry Age-related Macular Degeneration","enrollment":98},{"nctId":"NCT06943846","phase":"NA","title":"Platelet-Rich Fibrinogen in Extraction Socket Healing of the Aged","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2025-05-01","conditions":"Edentulism","enrollment":12},{"nctId":"NCT07366606","phase":"NA","title":"Bleeding Management İn Open Heart Surgery","status":"NOT_YET_RECRUITING","sponsor":"Serkan Uckun","startDate":"2026-04","conditions":"Thromboelastography (TEG), Open Heart Surgery, Bleeding","enrollment":140},{"nctId":"NCT03064152","phase":"NA","title":"Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-01","conditions":"Postpartum Hemorrhage","enrollment":49},{"nctId":"NCT04268940","phase":"","title":"Thrombo-Elastography Guided Management of ECMO","status":"COMPLETED","sponsor":"Damian Ratano","startDate":"2020-06-03","conditions":"Extracorporeal Circulation of Blood; Thrombocytopenia","enrollment":61},{"nctId":"NCT03255174","phase":"PHASE3","title":"The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study","status":"COMPLETED","sponsor":"Ethicon, Inc.","startDate":"2018-03-20","conditions":"Controlling Mild to Moderate Bleeding During Surgery","enrollment":35},{"nctId":"NCT07323342","phase":"NA","title":"Effectiveness and Safety of Intra-Articular Hyaluronic Acid Combined With Fibrinogen in Knee Osteoarthritis","status":"RECRUITING","sponsor":"Cao Kim Xoa","startDate":"2025-05-05","conditions":"Knee Osteoarthritis","enrollment":31},{"nctId":"NCT03253263","phase":"PHASE2","title":"A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants","status":"RECRUITING","sponsor":"OHB Neonatology Ltd.","startDate":"2019-05-09","conditions":"Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage","enrollment":338},{"nctId":"NCT07320378","phase":"EARLY_PHASE1","title":"Clinical Study on the Safety and Efficacy of Tendon Stem Progenitor Cells Therapy for Rotator Cuff Tears","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05","conditions":"Rotator Cuff Tendinopathy","enrollment":107},{"nctId":"NCT07263347","phase":"","title":"DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2025-12","conditions":"Breast Neoplasms, Ischemia-Reperfusion Injury, Postoperative Complications","enrollment":30},{"nctId":"NCT03269721","phase":"","title":"COPD-Related Physiology and the Brain","status":"COMPLETED","sponsor":"Karin Hoth","startDate":"2017-05-01","conditions":"Pulmonary Disease, Chronic Obstructive (COPD), Cognitive Impairment","enrollment":170},{"nctId":"NCT05091684","phase":"PHASE2","title":"Administration of Fibrinogen Concentrate for Refractory Bleeding","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2022-02-10","conditions":"Hematological Patients, Bleeding, Platelet Refractoriness","enrollment":1},{"nctId":"NCT02352181","phase":"NA","title":"Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment.","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-12","conditions":"Liver Transplantation","enrollment":82},{"nctId":"NCT07271212","phase":"NA","title":"Scalp Care Efficacy Evaluation for Premium Revitalizing Elixir","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hungkuang University","startDate":"2025-11-01","conditions":"Scalp Health, Hair Condition, Hair Loss","enrollment":60},{"nctId":"NCT06637943","phase":"","title":"Comparison of the Diagnosis Time of VET and SCL in Patients With Intraoperative Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"Konkuk University Medical Center","startDate":"2026-02-01","conditions":"Arthritis of Knee, Arthritis of Hip, Spine","enrollment":210},{"nctId":"NCT07265843","phase":"PHASE4","title":"Fibrinogen in Liver Transplant","status":"NOT_YET_RECRUITING","sponsor":"Trauma Hemostatis and Oxygenation Research (THOR) Network","startDate":"2026-01-01","conditions":"Liver Transplant Surgery","enrollment":60},{"nctId":"NCT05711524","phase":"PHASE4","title":"Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-04-01","conditions":"Hypofibrinogenemia, Bleeding","enrollment":208},{"nctId":"NCT06944275","phase":"","title":"Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2026-05-01","conditions":"Haemorrhagic Fever With Renal Syndrome","enrollment":62},{"nctId":"NCT07211841","phase":"NA","title":"Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-12","conditions":"Glioblastoma, MRI Spectroscopy, Tumor Microenvironment","enrollment":30},{"nctId":"NCT07218185","phase":"","title":"Comparative Effectiveness of INTERCEPT Fibrinogen Complex (IFC) and Cryoprecipitate-AHF (Cryo-AHF) for Treatment of Trauma Associated Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Cerus Corporation","startDate":"2026-05","conditions":"Hypofibrinogenemia, Hemorrhage","enrollment":320},{"nctId":"NCT07216157","phase":"NA","title":"NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery","status":"RECRUITING","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2025-08-15","conditions":"CerebroSpinal Fluid (CSF) Leak","enrollment":225},{"nctId":"NCT06095752","phase":"","title":"Multiple Myeloma Prognostic Indices","status":"COMPLETED","sponsor":"Assiut University","startDate":"2023-04-01","conditions":"Multiple Myeloma, Hematologic Diseases","enrollment":48},{"nctId":"NCT06255002","phase":"","title":"Concordance Between the Measurement of Whole Blood Fibrinogen by the qLabs®FIB Analyzer and Its Measurement by Conventional Method (Clauss Fibrinogen) in the Context of Severe Postpartum Haemorrhage","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-03","conditions":"Postpartum Hemorrhage","enrollment":70},{"nctId":"NCT06814730","phase":"PHASE1","title":"A Study to Assess THN391 in Subjects With Alzheimer's Disease","status":"RECRUITING","sponsor":"Therini Bio, Inc.","startDate":"2025-07-17","conditions":"Alzheimer Disease, Early Onset","enrollment":15},{"nctId":"NCT06003400","phase":"NA","title":"Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the \"FITT\" Device in Diabetic Foot Ulcers Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tri.O Medical LTD","startDate":"2023-03-29","conditions":"Diabetic Foot Ulcer","enrollment":20},{"nctId":"NCT06985121","phase":"NA","title":"Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence","status":"COMPLETED","sponsor":"Hungkuang University","startDate":"2025-04-08","conditions":"Scalp Health, Hair Condition, Hair Loss","enrollment":60},{"nctId":"NCT07127718","phase":"PHASE2","title":"Preventive Strategies for Early and Late Complications of Leptospirosis","status":"RECRUITING","sponsor":"National Kidney and Transplant Institute, Philippines","startDate":"2024-04-12","conditions":"Leptospirosis","enrollment":678},{"nctId":"NCT06764927","phase":"PHASE4","title":"Fibrinogen in Liver Transplant Subjects","status":"NOT_YET_RECRUITING","sponsor":"Ezeldeen Abuelkasem","startDate":"2025-10-31","conditions":"Liver Transplant Surgery","enrollment":30},{"nctId":"NCT05300672","phase":"PHASE3","title":"Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)","status":"COMPLETED","sponsor":"Azienda Usl di Bologna","startDate":"2022-02-08","conditions":"Intracranial Hemorrhages, Ischemic Stroke","enrollment":207},{"nctId":"NCT07074028","phase":"NA","title":"Characterization and Longitudinal Monitoring of Muscular Phenotype in Patients Admitted to Intensive Care for Sepsis","status":"RECRUITING","sponsor":"Centre Hospitalier de Saint-Brieuc","startDate":"2025-03-25","conditions":"Sepsis, Myopathy Critical Illness","enrollment":63},{"nctId":"NCT06144112","phase":"PHASE4","title":"Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery","status":"NOT_YET_RECRUITING","sponsor":"Konkuk University Medical Center","startDate":"2025-09-01","conditions":"Liver Diseases","enrollment":92},{"nctId":"NCT07043556","phase":"","title":"Assessment of Artificial Intelligence Algorithms for ROTEM","status":"RECRUITING","sponsor":"Ondokuz Mayıs University","startDate":"2025-07-01","conditions":"Coagulopathy","enrollment":144},{"nctId":"NCT06820879","phase":"NA","title":"Viscoelastic Tests (VET) Versus Conventional Coagulation Tests (CCT) for Management of Trauma-Induced Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-10-01","conditions":"Trauma Coagulopathy","enrollment":316},{"nctId":"NCT02065882","phase":"PHASE3","title":"Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency","status":"COMPLETED","sponsor":"Biotest","startDate":"2013-03","conditions":"Congenital Afibrinogenemia, Congenital Hypofibrinogenemia","enrollment":67},{"nctId":"NCT06480994","phase":"","title":"Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support","status":"RECRUITING","sponsor":"Diagnostica Stago R&D","startDate":"2022-06-21","conditions":"Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis","enrollment":1836},{"nctId":"NCT03793426","phase":"","title":"Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency","status":"TERMINATED","sponsor":"Octapharma","startDate":"2021-01-28","conditions":"Congenital Fibrinogen Deficiency","enrollment":7},{"nctId":"NCT03444324","phase":"PHASE3","title":"Adjusted Fibrinogen Replacement Strategy","status":"COMPLETED","sponsor":"Biotest","startDate":"2018-04-03","conditions":"Bleeding Disorder, Hypofibrinogenemia; Acquired","enrollment":222},{"nctId":"NCT06868823","phase":"","title":"Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2025-05-01","conditions":"Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT03598907","phase":"","title":"Point-of-care Management of Coagulopathy in Lung Transplantation","status":"TERMINATED","sponsor":"University Hospital, Motol","startDate":"2018-01-01","conditions":"Lung Transplantation","enrollment":100},{"nctId":"NCT05929326","phase":"","title":"Reference Intervals of Complete Blood Count and Coagulation Tests in Pregnant Women at Hung Vuong Hospital","status":"COMPLETED","sponsor":"Hung Vuong Hospital","startDate":"2023-06-09","conditions":"Pregnancy Related","enrollment":879},{"nctId":"NCT02887820","phase":"NA","title":"Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)","status":"TERMINATED","sponsor":"Stephen Esper","startDate":"2017-12-15","conditions":"Heart Disease, Lung Disease","enrollment":15},{"nctId":"NCT02375620","phase":"PHASE2","title":"Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2015-04-23","conditions":"Short Stature Children Born Small for Gestational Age (SGA)","enrollment":96},{"nctId":"NCT06903611","phase":"PHASE3","title":"Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Cambium Bio Limited","startDate":"2025-09-30","conditions":"Dry Eye Disease, Dry Eye, Dry Eyes Chronic","enrollment":400},{"nctId":"NCT06434389","phase":"","title":"A Point-of-care Electrochemical-based Device for Rapid Detection of Fibrinogen on Type A Aortic Dissection Surgery","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-06-01","conditions":"Hypofibrinogenemia","enrollment":150},{"nctId":"NCT03572309","phase":"","title":"Incidence of Trauma Induced Coagulopathy in Patients With Prehospital Administration of Fibrinogen","status":"COMPLETED","sponsor":"Masaryk University","startDate":"2018-06-19","conditions":"Trauma, Hemorrhage, Coagulopathy","enrollment":28},{"nctId":"NCT04301193","phase":"","title":"Evaluation of Novel Point of Care Coagulation System in Pregnant Women","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-11-01","conditions":"Hemorrhage, Coagulation Delay","enrollment":13},{"nctId":"NCT05935137","phase":"","title":"Evaluation of Coagulation Status of Pregnant Women in the Peripartum Period Using the Device Clotpro®","status":"COMPLETED","sponsor":"Ondrej Hrdy","startDate":"2023-05-26","conditions":"Coagulation and Hemorrhagic Disorders","enrollment":175},{"nctId":"NCT06192199","phase":"","title":"The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-01-01","conditions":"Acute Pulmonary Embolism","enrollment":800},{"nctId":"NCT05842096","phase":"NA","title":"Subclinical Hypothyroidism and Chronic Inflammation in PCOS","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2024-01-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Subclinical hypothyroïdism, Hypothalamic-Pituitary-Gonadal Axis Dysfunction","enrollment":158},{"nctId":"NCT06183307","phase":"NA","title":"Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia","status":"RECRUITING","sponsor":"Universidade Federal Fluminense","startDate":"2024-08-03","conditions":"Cardiovascular Diseases, Dyslipidemias, Inflammation","enrollment":48},{"nctId":"NCT02583763","phase":"","title":"Cardiac Displacement From Third Trimester to Early Childhood","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Linkoeping","startDate":"2013-01","conditions":"IUGR, Fetal Growth Retardation, Intrauterine Growth Restriction","enrollment":61},{"nctId":"NCT04660721","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery","status":"COMPLETED","sponsor":"Sealantium Medical Ltd.","startDate":"2021-05-12","conditions":"Hemostasis, General Surgery","enrollment":33},{"nctId":"NCT06328647","phase":"NA","title":"Quantra Point-of-Care Hemostasis Monitoring","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2024-10-03","conditions":"Bleeding, Hemostatic Disorder","enrollment":666},{"nctId":"NCT06860503","phase":"","title":"Thrombelastography for Coagulopathy in Chinese Snakebites","status":"COMPLETED","sponsor":"Hansung University","startDate":"2015-01-01","conditions":"Pit Viper Bite, Coagulopathy, Thromboelastography (TEG)","enrollment":61},{"nctId":"NCT06850532","phase":"NA","title":"NMES Effects on Substrate Metabolism and IGF-1","status":"COMPLETED","sponsor":"Mersin University","startDate":"2017-03-17","conditions":"The Effects of Neuromuscular Electrical Stimulation on Exercise Performance","enrollment":24},{"nctId":"NCT06455553","phase":"NA","title":"Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L.","status":"COMPLETED","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2024-06-26","conditions":"Hematologic Malignancies, Thrombopenia","enrollment":48},{"nctId":"NCT06814990","phase":"NA","title":"Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients with Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement","status":"RECRUITING","sponsor":"Stephanie Gräger","startDate":"2024-04-19","conditions":"MASLD, Liver Cirrhosis, Alcoholic, Cirrhosis of Liver","enrollment":80},{"nctId":"NCT03932162","phase":"EARLY_PHASE1","title":"Gene Expression Changes In Young and Geriatric Skin","status":"RECRUITING","sponsor":"Wright State University","startDate":"2019-09-06","conditions":"UVB Phototherapy Burn, Insulin-like Growth Factor 1, Aging","enrollment":24},{"nctId":"NCT02398656","phase":"PHASE3","title":"A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-04-01","conditions":"Stroke, Acute","enrollment":1274},{"nctId":"NCT04704869","phase":"PHASE3","title":"Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation","status":"COMPLETED","sponsor":"Bryan Cotton","startDate":"2017-01","conditions":"Trauma Injury","enrollment":1604},{"nctId":"NCT06021184","phase":"","title":"\"ADE Fibrinogen/RBC\" Ratio on Mortality and Outcome in Massive Transfusion Patients","status":"RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2023-11-07","conditions":"Massive Transfusion, Bleeding During/following Surgery","enrollment":1679},{"nctId":"NCT04602689","phase":"NA","title":"Fibrin Glue After ESD for High Risk Patients of Bleeding","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-10-30","conditions":"Early Gastric Cancer, Gastric Adenoma","enrollment":134},{"nctId":"NCT04918108","phase":"","title":"Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Cohort Study) III","status":"COMPLETED","sponsor":"Nanjing Medical University","startDate":"2021-01-01","conditions":"Aortic Dissection","enrollment":2000},{"nctId":"NCT05703126","phase":"NA","title":"Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML","status":"RECRUITING","sponsor":"Samara State Medical University","startDate":"2022-12-01","conditions":"Acute Myeloid Leukemia, Adult, Cardiotoxicity, Endothelial Dysfunction","enrollment":100},{"nctId":"NCT06668948","phase":"","title":"The Prognostic Role of Fibrinogen to Albumin Ratio in Acute Leukemia Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-10-01","conditions":"Patients with Acute Leukemia","enrollment":90},{"nctId":"NCT06667882","phase":"NA","title":"Safe Delivery of Thrombolytic Treatment for Pulmonary Embolism Using ClotPro® Viscoelastic Tests","status":"COMPLETED","sponsor":"Semmelweis University","startDate":"2021-12-17","conditions":"Pulmonary Embolism Subacute Massive, Complication of Treatment, Fibrinolysis; Hemorrhage","enrollment":33},{"nctId":"NCT06320236","phase":"","title":"Emergency Medicine Pulmonary Embolism Testing Multicentre Study","status":"RECRUITING","sponsor":"Dr. Kerstin de Wit","startDate":"2024-01-01","conditions":"Pulmonary Embolism, D-dimer, Diagnosis","enrollment":4000},{"nctId":"NCT05218356","phase":"PHASE2","title":"Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2022-01-20","conditions":"COVID-19","enrollment":130},{"nctId":"NCT06614998","phase":"","title":"Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2024-05-01","conditions":"Hemophagocytic Syndrome","enrollment":80},{"nctId":"NCT06582420","phase":"NA","title":"Pre-hospital Administration of Fibrinogen in Trauma-Induced Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"Unidade Local de Saude do Arco Ribeirinho","startDate":"2025-01-01","conditions":"Trauma Induced Coagulopathy","enrollment":52},{"nctId":"NCT05379530","phase":"NA","title":"TEG Use in Children Undergoing Procedures With High Anticipated Blood Loss","status":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-01-01","conditions":"Surgical Blood Loss, Surgical Hemorrhage, Post Operative Hemorrhage","enrollment":60},{"nctId":"NCT06429540","phase":"NA","title":"Post Extraction Changes Following Ridge Preservation Using Partially Demineralized Dentin Block Versus Xenograft","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-03-01","conditions":"Socket Preservation","enrollment":22},{"nctId":"NCT06153082","phase":"NA","title":"Rotational Thromboelastometry [ROTEM] vs Thromboelastography [TEG] Guided Blood Component Use in Patients With Cirrhosis of Liver With Non-variceal Bleeding.","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-12-16","conditions":"Liver Cirrhosis","enrollment":80},{"nctId":"NCT06275490","phase":"NA","title":"Post Extraction Changes Following Ridge Preservation Using Partially Demineralized Dentin Block Versus L- PRF Block","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2024-01-01","conditions":"Socket Preservation","enrollment":20},{"nctId":"NCT04912336","phase":"","title":"Extracorporeal Life Support and Modification of Hemostasis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2021-05-28","conditions":"Bleeding Disorder, Extra Corporeal Life Support, Thrombosis","enrollment":43},{"nctId":"NCT06420713","phase":"NA","title":"Horizontal Bone Augmentation of Alveolar Ridge","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2019-10-20","conditions":"Platelet-rich Fibrin, Bone Substitutes, Atrophic Maxilla","enrollment":28},{"nctId":"NCT05607602","phase":"","title":"Are Uterine Fibroids Pro-thrombotic?","status":"ACTIVE_NOT_RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2022-10-17","conditions":"Leiomyoma, Uterine, Thrombosis","enrollment":105}],"_emaApprovals":[],"_faersSignals":[{"count":58,"reaction":"OFF LABEL USE"},{"count":57,"reaction":"DRUG INEFFECTIVE"},{"count":40,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"},{"count":34,"reaction":"HYPOTENSION"},{"count":34,"reaction":"SHOCK HAEMORRHAGIC"},{"count":31,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"},{"count":30,"reaction":"PLEURAL EFFUSION"},{"count":29,"reaction":"BLOOD PRESSURE INCREASED"},{"count":29,"reaction":"PNEUMONIA"},{"count":28,"reaction":"FOETAL GROWTH RESTRICTION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical"},"crossReferences":{"chemblId":"CHEMBL2109072"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":57587,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Fibrinogen","genericName":"Fibrinogen","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:16:35.606596+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}